Open AccessA POSSIBLE PREDICTIVE TEST FOR GRAFT-VERSUS-HOST DISEASE IN BONE MARROW GRAFT RECIPIENTS
Author(s) -
Martine Bagot,
Catherine Cordonnier,
A F Tilkin,
Michèle Heslan,
Jean Paul Vernant,
Louis Dubertret,
J. P. Lévy
Publication year - 1986
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-198603000-00007
Subject(s) - minor histocompatibility antigen , histocompatibility , immunology , human leukocyte antigen , bone marrow , antigen , graft versus host disease , medicine , mixed lymphocyte reaction , graft vs host reaction , in vitro , major histocompatibility complex , disease , lymphocyte , t cell , bone marrow transplantation , immune system , biology , pathology , biochemistry
The possible ability of the mixed-epidermal-cell-lymphocyte reaction (MECLR) to detect alloreactivities in HLA-identical MLR negative siblings has been investigated before grafting in 30 donor-recipients pairs and their families. Results indicate that recipients' epidermal cells (EC) can induce proliferative responses of HLA-identical MLR-negative donors' lymphocytes in 55% of the pairs tested. Moreover, further evaluation of 21 patients shows that the positivity of the MECLR before the graft is correlated with later appearance of acute and chronic GVHD, and especially with the severity of cutaneous injury. EC have been shown to be more efficient antigen presenting cells than peripheral blood lymphocytes for in vitro primary proliferative responses, so these reactions could be directed against some minor histocompatibility antigens, thus leading to possible improvement in selecting bone marrow graft donors and to the detection of donor-recipient pairs with a high risk of GVHD.